Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64494 | 0.88 | CA2 (0.43) | KMT2AMEN1ALDH1A1NR1H3PTGS1 | |
| SCHEMBL15082546 | 0.84 | ALDH1A1 (0.37) | KMT2AMEN1ALDH1A1NR1H3PTGS1 | |
| SCHEMBL2513199 | 0.81 | NR3C2 (0.44) | KMT2AMEN1ALDH1A1NR3C2CA9 | |
| SCHEMBL16300054 | 0.78 | MEN1 (0.33) | KMT2AMEN1ALDH1A1NR1H3PTGS1 | |
| SCHEMBL10059165 | 0.78 | HSP90AA1 (0.36) | KMT2AMEN1ALDH1A1NR1H3PTGS1 | |
| SCHEMBL17464348 | 0.78 | NR3C2 (0.39) | KMT2AMEN1ALDH1A1NR3C2PTPN1 | |
| SCHEMBL11512437 | 0.78 | KMT2A (0.36) | KMT2AMEN1ALDH1A1NR1H3NR3C2 | |
| SCHEMBL29279172 | 0.77 | ALDH1A1 (0.33) | KMT2AMEN1ALDH1A1NR1H3PTGS1 | |
| SCHEMBL6191256 | 0.77 | GRM2 (0.39) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL28384073 | 0.77 | CA2 (0.35) | KMT2AMEN1ALDH1A1NR1H3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003002548-A1 | A PROCESS FOR THE PREPARATION OF CHIRAL GLUCOCORTICOID RECEPTOR AGENTS | ABBOTT LABORATORIES (US) | 2003-01-09 | — | — | WO | claimed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4434990-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024192309-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240218013-A1 | Process for the preparation of B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl) sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| WO-2024080788-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | 한미약품 주식회사 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024009325-A1 | Solid state forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and processes for preparation thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-01-11 | — | — | WO | disclosed |
| US-11805697-B2 | Organic electroluminescence device and monoamine compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-31 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11713313-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-01 | — | — | US | disclosed |
| US-20120231543-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012019954-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | EVOTEC (UK) LTD. (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009121872-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1513793-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101928-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231543-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | KMT2A 2033/4885MEN1 4879/4885ALDH1A1 761/4885 |
| US-20240218013-A1 | Process for the preparation of B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl) sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and intermediates of said process | CYP19A1, HSD17B11, NR5A1 | KMT2A 1601/4885MEN1 1327/4885ALDH1A1 1682/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | KMT2A 1463/4885MEN1 1674/4885ALDH1A1 798/4885 |
| US-20090221562-A1 | NOVEL OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRL1 | KMT2A 2033/4885MEN1 4879/4885ALDH1A1 761/4885 |
| US-11805697-B2 | Organic electroluminescence device and monoamine compound for organic electroluminescence device | SLC18A2, SLC18A1, MAOA | KMT2A 1302/4885MEN1 2341/4885ALDH1A1 89/4885 |
| US-11713313-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | KMT2A 2651/4885MEN1 1849/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.